(3Z)-3-(quinolin-4-ylmethylidene)-1H-indol-2-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: (3Z)-3-(quinolin-4-ylmethylidene)-1H-indol-2-one
• 化学式: C₁₈H₁₂N₂O
• 分子量: 272.306
• InChiKey: UBEIHUVCYODJRE-PTNGSMBKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  42
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-喹啉甲醛 、 2-吲哚酮 在 盐酸 作用下， 以 溶剂黄146 为溶剂， 反应 3.0h， 以50%的产率得到(3Z)-3-(quinolin-4-ylmethylidene)-1H-indol-2-one
  参考文献：
  名称：

  Buzzetti, Franco; Pinciroli, Vittorio; Brasca, M. Gabriella, Gazzetta Chimica Italiana, 1995, vol. 125, # 2, p. 69 - 76

  摘要：

  DOI：

文献信息

• Indolinone derivatives and their use in treating disease-states such as cancer
  申请人：Arnaiz Damian

  公开号：US20050090541A1

  公开（公告）日：2005-04-28

  Indolinone derivatives, such as compounds of the formula (I): wherein A, m, n, R 1 , R 2 , R 3 , R 5 and R 6 are described herein, are disclosed herein as being useful in treating mammal having disease-states alleviated by the inhibition of PDK-1 activity.

  Indolinone衍生物，例如公式（I）中的化合物：其中A，m，n，R1，R2，R3，R5和R6如本文所述，据本文披露，可用于治疗通过抑制PDK-1活性缓解疾病状态的哺乳动物。
• 2-Oxindole derivatives as tyrosine kinase inhibitors
  申请人：PHARMACIA & UPJOHN S.p.A.

  公开号：EP0662473B1

  公开（公告）日：1999-09-01
• INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER
  申请人：Schering Aktiengesellschaft

  公开号：EP1680401A2

  公开（公告）日：2006-07-19
• METHODS OF TREATING MUSCULAR DYSTROPHY
  申请人：BURKIN Dean

  公开号：US20160030390A1

  公开（公告）日：2016-02-04

  Disclosed herein are α7β1 integrin modulatory agents and methods of using such to treat conditions associated with decreased α7β1 integrin expression or activity, including muscular dystrophy. In one example, methods for treating a subject with muscular dystrophy are disclosed. The methods include administering an effective amount of an α7β1 integrin modulatory agent to the subject with muscular dystrophy, wherein the α7β1 integrin modulatory agent increases α7β1 integrin expression or activity as compared to α7β1 integrin expression or activity prior to treatment, thereby treating the subject with muscular dystrophy. Also disclosed are methods of enhancing muscle regeneration, repair, or maintenance in a subject and methods of enhancing α7β1 integrin expression by use of the disclosed α7β1 integrin modulatory agents. Methods of prospectively preventing or reducing muscle injury or damage in a subject are also disclosed.
• US7105563B2
  申请人：——

  公开号：US7105563B2

  公开（公告）日：2006-09-12